Profile - To The Moon

jazlynnsee

Posts · 4Posts · 4
Following · 0Following · 0
Followers · 0Followers · 0

- jazlynnseejazlynnsee
  ·2021-02-06
  moon
  The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market
  Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Jan. 25)
  The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market
  148 Comment
  1
  Share
  Report
- jazlynnseejazlynnsee
  ·2021-01-28
  moon
  GameStop up another 60%, amateur interest shows no sign of abating
  LONDON, Jan 27 (Reuters) - GameStop shares surged another 60% on Wednesday in pre-market trading, bo
  GameStop up another 60%, amateur interest shows no sign of abating
  154 Comment
  1
  Share
  Report
- jazlynnseejazlynnsee
  ·2021-01-28
  okay
  Airbnb was ensnared in the Capitol Riot fallout. It somehow still came out on top
  Washington, DCBrian Chesky had some air mattresses, but not much more, in 2008 when the presidential
  Airbnb was ensnared in the Capitol Riot fallout. It somehow still came out on top
  260 Comment
  2
  Share
  Report
- jazlynnseejazlynnsee
  ·2021-01-28
  wow
  Goldman Sachs loses legal fight against EU cartel fine
  BRUSSELS, Jan 27 (Reuters) - U.S. investment bank Goldman Sachs on Wednesday lost its fight against
  Goldman Sachs loses legal fight against EU cartel fine
  356 1
  Like
  Share
  Report

Most Discussed

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"isCurrentUser":false,"userPageInfo":{"id":"3572496339521414","uuid":"3572496339521414","gmtCreate":1609404076975,"gmtModify":1609404076975,"name":"jazlynnsee","pinyin":"jazlynnsee","introduction":"","introductionEn":null,"signature":"","avatar":"https://static.laohu8.com/default-avatar.jpg","hat":null,"hatId":null,"hatName":null,"vip":1,"status":2,"fanSize":0,"headSize":2,"tweetSize":4,"questionSize":0,"limitLevel":999,"accountStatus":4,"level":{"id":0,"name":"","nameTw":"","represent":"","factor":"","iconColor":"","bgColor":""},"themeCounts":0,"badgeCounts":0,"badges":[],"moderator":false,"superModerator":false,"manageSymbols":null,"badgeLevel":null,"boolIsFan":false,"boolIsHead":false,"favoriteSize":0,"symbols":null,"coverImage":null,"realNameVerified":"success","userBadges":[{"badgeId":"1026c425416b44e0aac28c11a0848493-2","templateUuid":"1026c425416b44e0aac28c11a0848493","name":"Senior Tiger","description":"Join the tiger community for 1000 days","bigImgUrl":"https://static.tigerbbs.com/0063fb68ea29c9ae6858c58630e182d5","smallImgUrl":"https://static.tigerbbs.com/96c699a93be4214d4b49aea6a5a5d1a4","grayImgUrl":"https://static.tigerbbs.com/35b0e542a9ff77046ed69ef602bc105d","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.09.27","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1001},{"badgeId":"44212b71d0be4ec88898348dbe882e03-1","templateUuid":"44212b71d0be4ec88898348dbe882e03","name":"Boss Tiger","description":"The transaction amount of the securities account reaches $100,000","bigImgUrl":"https://static.tigerbbs.com/c8dfc27c1ee0e25db1c93e9d0b641101","smallImgUrl":"https://static.tigerbbs.com/f43908c142f8a33c78f5bdf0e2897488","grayImgUrl":"https://static.tigerbbs.com/82165ff19cb8a786e8919f92acee5213","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2023.07.14","exceedPercentage":"60.87%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1101},{"badgeId":"7a9f168ff73447fe856ed6c938b61789-1","templateUuid":"7a9f168ff73447fe856ed6c938b61789","name":"Knowledgeable Investor","description":"Traded more than 10 stocks","bigImgUrl":"https://static.tigerbbs.com/e74cc24115c4fbae6154ec1b1041bf47","smallImgUrl":"https://static.tigerbbs.com/d48265cbfd97c57f9048db29f22227b0","grayImgUrl":"https://static.tigerbbs.com/76c6d6898b073c77e1c537ebe9ac1c57","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1102},{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":null,"individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100},{"badgeId":"972123088c9646f7b6091ae0662215be-2","templateUuid":"972123088c9646f7b6091ae0662215be","name":"Master Trader","description":"Total number of securities or futures transactions reached 100","bigImgUrl":"https://static.tigerbbs.com/ad22cfbe2d05aa393b18e9226e4b0307","smallImgUrl":"https://static.tigerbbs.com/36702e6ff3ffe46acafee66cc85273ca","grayImgUrl":"https://static.tigerbbs.com/d52eb88fa385cf5abe2616ed63781765","redirectLinkEnabled":0,"redirectLink":null,"hasAllocated":1,"isWearing":0,"stamp":null,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","exceedPercentage":"80.73%","individualDisplayEnabled":0,"backgroundColor":null,"fontColor":null,"individualDisplaySort":0,"categoryType":1100}],"userBadgeCount":5,"currentWearingBadge":null,"individualDisplayBadges":null,"crmLevel":2,"crmLevelSwitch":0,"location":null,"starInvestorFollowerNum":0,"starInvestorFlag":false,"starInvestorOrderShareNum":0,"subscribeStarInvestorNum":0,"ror":null,"winRationPercentage":null,"showRor":false,"investmentPhilosophy":null,"starInvestorSubscribeFlag":false},"page":1,"watchlist":null,"tweetList":[{"id":380577109,"gmtCreate":1612569417501,"gmtModify":1704872934454,"author":{"id":"3572496339521414","authorId":"3572496339521414","name":"jazlynnsee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572496339521414","authorIdStr":"3572496339521414"},"themes":[],"htmlText":"moon","listText":"moon","text":"moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/380577109","repostId":"2106729114","repostType":2,"repost":{"id":"2106729114","weMediaInfo":{"introduction":"Stock Market Quotes, Business News, Financial News, Trading Ideas, and Stock Research by Professionals","home_visible":0,"media_name":"Benzinga","id":"1052270027","head_image":"https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa"},"pubTimestamp":1611670059,"share":"https://ttm.financial/m/news/2106729114?lang=&edition=fundamental","pubTime":"2021-01-26 22:07","market":"us","language":"en","title":"The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market","url":"https://stock-news.laohu8.com/highlight/detail?id=2106729114","media":"Benzinga","summary":"Here&#39;s a roundup of top developments in the biotech space over the last 24 hours:\n\nScaling The Peaks\n\n(Biotech Stocks Hitting 52-week Highs Jan. 25)","content":"<html><body><p>Here's a roundup of top developments in the biotech space over the last 24 hours:</p>\n<h3>Scaling The Peaks</h3>\n<p>(Biotech Stocks Hitting 52-week Highs Jan. 25)</p>\n<ul>\n<li><strong>Abbott Laboratories </strong>(NYSE:ABT)</li>\n<li><strong>Alexion Pharmaceuticals, Inc. </strong>(NASDAQ:ALXN)</li>\n<li><strong>Alnylam Pharmaceuticals, Inc. </strong>(NASDAQ:ALNY)</li>\n<li><strong>Antares Pharma Inc </strong>(NASDAQ:ATRS)</li>\n<li><strong><a href=\"https://laohu8.com/S/AMTI\">Applied Molecular Transport Inc.</a> </strong>(NASDAQ:AMTI)</li>\n<li><strong>argenx SE – ADR </strong>(NASDAQ:ARGX)</li>\n<li><strong><a href=\"https://laohu8.com/S/AUPH\">Aurinia Pharmaceuticals Inc</a> </strong>(NASDAQ:AUPH) (announced FDA approval for its oral lupus nephritis drug)</li>\n<li><strong>Axonics Modulation Technologies Inc </strong>(NASDAQ:AXNX)</li>\n<li><strong>Beigene Ltd </strong>(NASDAQ:BGNE)</li>\n<li><strong>BioNano Genomics Inc </strong>(NASDAQ:BNGO) (reacted to positive sell-side commentary)</li>\n<li><strong><a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a> </strong>(NASDAQ:SAVA)</li>\n<li><strong><a href=\"https://laohu8.com/S/CCXI\">ChemoCentryx</a> Inc </strong>(NASDAQ:CCXI)</li>\n<li><strong>Clearpoint Neuro Inc </strong>(NASDAQ:CLPT)</li>\n<li><strong>DarioHealth Corp </strong>(NASDAQ:DRIO)</li>\n<li><strong>DermTech Inc </strong>(NASDAQ:DMTK)</li>\n<li><strong><a href=\"https://laohu8.com/S/EDAP\">Edap Tms SA</a></strong>(NASDAQ:EDAP)</li>\n<li><strong>Eli Lilly And Co </strong>(NYSE:LLY) (reacted to positive Phase 3 data for its COVID-19 antibody treatment bamlanivimab)</li>\n<li><strong><a href=\"https://laohu8.com/S/EKSO\">Ekso Bionics Holdings Inc</a> </strong>(NASDAQ:EKSO)</li>\n<li><strong><a href=\"https://laohu8.com/S/NDRA\">ENDRA Life Sciences Inc</a> </strong>(NASDAQ:NDRA)</li>\n<li><strong>Evogene Ltd </strong>(NASDAQ:EVGN)</li>\n<li><strong>EXACT Sciences Corporation </strong>(NASDAQ:EXAS)</li>\n<li><strong>GW Pharmaceuticals <a href=\"https://laohu8.com/S/PLC\">PLC</a>- ADR </strong>(NASDAQ:GWPH)</li>\n<li><strong>Halozyme Therapeutics, Inc. </strong>(NASDAQ:HALO)</li>\n<li><strong>Harvard Bioscience, Inc. </strong>(NASDAQ:HBIO)</li>\n<li><strong><a href=\"https://laohu8.com/S/ILMN\">Illumina</a>, Inc. </strong>(NASDAQ:ILMN)</li>\n<li><strong>Inari Medical Inc </strong>(NASDAQ:NARI)</li>\n<li><strong><a href=\"https://laohu8.com/S/INSM\">Insmed</a> Incorporated </strong>(NASDAQ:INSM)</li>\n<li><strong>Ionis Pharmaceuticals Inc </strong>(NASDAQ:IONS)</li>\n<li><strong>Jazz Pharmaceuticals PLC </strong>(NASDAQ: JAZZ</li>\n<li><strong>Jounce Therapeutics Inc</strong>(NASDAQ:JNCE)</li>\n<li><strong>Kintara Therapeutics Inc </strong>(NASDAQ:KTRA)</li>\n<li><strong>Krystal Biotech Inc</strong>(NASDAQ:KRYS)</li>\n<li><strong>LeMaitre Vascular Inc </strong>(NASDAQ:LMAT)</li>\n<li><strong><a href=\"https://laohu8.com/S/LGND\">Ligand Pharmaceuticals Inc.</a> </strong>(NASDAQ:LGND)</li>\n<li><strong><a href=\"https://laohu8.com/S/MMSI\">Merit Medical Systems</a>, Inc. </strong>(NASDAQ:MMSI)</li>\n<li><strong>Mustang Bio Inc </strong>(NASDAQ:MBIO)</li>\n<li><strong><a href=\"https://laohu8.com/S/OMCL\">Omnicell</a>, Inc. </strong>(NASDAQ:OMCL)</li>\n<li><strong>Oramed Pharmaceuticals, Inc. </strong>(NASDAQ:ORMP)</li>\n<li><strong><a href=\"https://laohu8.com/S/PEN\">Penumbra Inc</a> </strong>(NYSE:PEN)</li>\n<li><strong>Profound Medical Corp</strong>(NASDAQ:PROF)</li>\n<li><strong>Pulse Biosciences Inc </strong>(NASDAQ:PLSE) (announced CE mark approval for the CellFX System for the treatment of general dermatologic conditions)</li>\n<li><strong>Renalytix AI PLC </strong>(NASDAQ:RNLX)</li>\n<li><strong>Rhythm Pharmaceuticals Inc </strong>(NASDAQ:RYTM)</li>\n<li><strong>Seelos Therapeutics Inc </strong>(NASDAQ:SEEL)</li>\n<li><strong>SI-Bone Inc </strong>(NASDAQ:SIBN)</li>\n<li><strong>Silence Therapeutics ADR Representing 3 Ord Shs </strong>(NASDAQ:SLN)</li>\n<li><strong>SpringWorks Therapeutics Inc </strong>(NASDAQ:SWTX)</li>\n<li><strong><a href=\"https://laohu8.com/S/SUPN\">Supernus Pharmaceuticals</a> Inc </strong>(NASDAQ:SUPN)</li>\n<li><strong><a href=\"https://laohu8.com/S/TMDI\">Titan Medical Inc.</a> </strong>(NASDAQ:TMDI)</li>\n<li><strong>Vericel Corp </strong>(NASDAQ:VCEL)</li>\n<li><strong>Vistagen Therapeutics Inc </strong>(NASDAQ:VTGN)</li>\n</ul>\n<h3>Down In The Dumps</h3>\n<p>None of the biotech/medical device/diagnostic stocks hit 52-week highs in the session.</p>\n<h3>Stocks In Focus</h3>\n<h3>Novartis Q4 Results Trail Expectations</h3>\n<p><strong>Novartis AG </strong>(NYSE:NVS) reported a 3% year-over-year increase in fourth-quarter sales to $12.77 billion. The core EPS increased from $1.32 to $1.34. Analysts, on average, estimated EPS of $1.36 on revenue of $12.87 billion.</p>\n<p>For 2021, the company expects constant currency sales growth in the low-to-mid single digit range and core operating income to rise in the mid-single digit range.</p>\n<p>The stock was down 3.77% to $94.76 premarket Tuesday.</p>\n<h3>Amarin Includes HealthNet In Patent Infringement Lawsuit</h3>\n<p><strong>Amarin Corporation plc </strong>(NASDAQ:AMRN) said it has expanded the scope of its  Vascepa patent infringement lawsuit  against Hikma Pharma to include Health Net, a health care insurance provider in the U.S.</p>\n<p>Amarin alleged that Health Net has actively induced pharmacies to dispense, and patients to use, Hikma generic icosapent ethyl capsules in infringement of three U.S. patents related to Vascepa.</p>\n<p>A vast majority of Vascepa prescriptions are for use in cardiovascular risk reduction, and Hikma does not have an FDA-approved indication for that use, and inducement for such use would infringe the subject patents, Amarin said.</p>\n<p>Amarin shares were rising 2.12% to $7.72 premarket Tuesday. </p>\n<h3>Spectrum Pharma Rises On Fund Stake Disclosure</h3>\n<p><strong><a href=\"https://laohu8.com/S/SPPI\">Spectrum Pharmaceuticals</a>, Inc. </strong>(NASDAQ:SPPI) shares rallied after <strong>BlackRock, Inc. </strong>(NYSE:BLK) revealed in a filing it beneficially owns an aggregate of 27.82 million shares in the company, giving it a 19.1% stake.</p>\n<p>The stock was up 2.55% to $4.02 premarket. </p>\n<p><em>Related Link: The Week Ahead In Biotech (Jan 24-30): J&amp;J, Lilly to Kickstart Big Pharma Earnings, Amgen FDA Decision and More </em></p>\n<h3>Lilly's Antibody Combo Treatment Aces Late-Stage Study In High-Risk COVID-19 Patients</h3>\n<p>Lilly said its bamlanivimab, 2,800 mg, and etesevimab, 2,800 mg, together significantly reduced COVID-19-related hospitalizations and deaths in high-risk patients recently diagnosed with COVID-19, meeting the primary endpoint of the Phase 3 BLAZE-1 trial.</p>\n<p>\"Notably, the 70 percent decrease in risk of hospitalizations or death seen in this Phase 3 trial of bamlanivimab and etesevimab together is consistent with the reduction in risk of hospitalization or ER visits seen with bamlanivimab alone in the Phase 2 trial,\" Lilly said.</p>\n<p>In premarket trading Tuesday, the shares were advancing 1.18% to $214.85. </p>\n<h3>Morphosys Set For $1.5M Milestone Payment From I-Mab As Phase 1 Study Of Monoclonal Antibody In Solid Tumors Commences</h3>\n<p><strong>I-Mab ADR </strong>(NASDAQ:IMAB) and <strong>Morphosys Ag </strong>(NASDAQ:MOR) announced the commencement of a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of MOR210/TJ210 monotherapy in patients with relapsed or refractory advanced solid tumors in the U.S., with the first patient being dosed.</p>\n<p>MOR210/TJ210 is a monoclonal antibody developed by MorphoSys that is directed against complement factor C5a receptor 1.</p>\n<p>MorphoSys will receive a $1.5-million payment from I-Mab for achieving this milestone under the license agreement between the two companies. The licensing deal between the companies announced in November 2018 provides I-Mab exclusive rights to develop and commercialize MOR210/TJ210 in Greater China and South Korea, while MorphoSys retains rights in other parts of the world.</p>\n<p>In premarket trading Tuesday, I-Mab shares were moving up 2.78% to $54.44.</p>\n<h3>Axonics Q4, FY20 Revenue Guidance Below Consensus Estimates</h3>\n<p>Axonics Modulation preannounced fourth-quarter revenue in the range of $34.7 million to $34.9 million, sharply higher than the $9.9 million in the year-ago quarter. For the full-year, the company expects revenue of about $111.5 million compared to the year-ago revenue of $13.8 million.</p>\n<p>The guidance range trailed the consensus estimates that call for revenue of $35.48 million for the quarter and $112.31 million for the year.</p>\n<h3>Merck's Keytruda Gets Label Expansion In Europe</h3>\n<p><strong>Merck &amp; Co., Inc. </strong>(NYSE:MRK) said the European Commission has approved its Keytruda as a monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.</p>\n<p>The stock was down 0.18% to $81 in premarket trading Tuesday.</p>\n<h3>Offerings</h3>\n<p>German  coronavirus vaccine developer  <strong>CureVac BV </strong>(NASDAQ:CVAC) announced an underwritten public offering of 5 million common shares.</p>\n<p>The stock was down 2.6% to $101.78 premarket Tuesday. </p>\n<p>Seelos said it has commenced a proposed underwritten public offering of shares of common stock. All of the shares of common stock in the offering will be sold by the company.</p>\n<p>The stock was tumbling 9.02% to $2.42 premarket Tuesday.</p>\n<p><strong><a href=\"https://laohu8.com/S/LPCN\">Lipocine Inc</a> </strong>(NASDAQ:LPCN) said it intends to offer shares of its common stock in an underwritten public offering. All of the shares in the proposed offering are to be sold by Lipocine.</p>\n<p>In premarket trading Tuesday, the stock was retreating 11.36% to $1.95. </p>\n<h3>On The Radar</h3>\n<p><strong>Clinical Readouts</strong></p>\n<p>Rhythm Pharma is hosting a virtual event from 8-10 a.m. Tuesday to provide an update on its ongoing exploratory Phase 2 Basket Study and genetic sequencing efforts.</p>\n<p>The company will present data for setmelanotide in individuals living with heterozygous obesity due to genetic variants in <a href=\"https://laohu8.com/S/AONE\">one</a> of two alleles of the POMC, PCSK1 or LEPR gene, as well as SRC1 and SH2B1 deficiency obesities.</p>\n<p>It will also provide an update on data from its sequencing efforts, which now comprise samples from approximately 37,500 individuals with severe obesity.</p>\n<h3>Earnings</h3>\n<p><strong>Johnson &amp; Johnson </strong>(NYSE:JNJ) (Q4 revenue of $22.48 billion vs. $21.67-billion estimate, adjusted EPS $1.86 vs. $1.82 consensus, FY21 adjusted EPS guidance above consensus)</p>\n<p><strong>Varian Medical Systems, Inc. </strong>(NYSE:VAR) (after the close)</p>\n<p><em>Related Link: Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates </em></p>\n</body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>The Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nThe Daily Biotech Pulse: Novartis Misses, J&J Beats In Big Pharma Earnings, Vaccine Developer CureVac Taps Equity Market\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/d08bf7808052c0ca9deb4e944cae32aa);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Benzinga </p>\n<p class=\"h-time\">2021-01-26 22:07</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p>Here's a roundup of top developments in the biotech space over the last 24 hours:</p>\n<h3>Scaling The Peaks</h3>\n<p>(Biotech Stocks Hitting 52-week Highs Jan. 25)</p>\n<ul>\n<li><strong>Abbott Laboratories </strong>(NYSE:ABT)</li>\n<li><strong>Alexion Pharmaceuticals, Inc. </strong>(NASDAQ:ALXN)</li>\n<li><strong>Alnylam Pharmaceuticals, Inc. </strong>(NASDAQ:ALNY)</li>\n<li><strong>Antares Pharma Inc </strong>(NASDAQ:ATRS)</li>\n<li><strong><a href=\"https://laohu8.com/S/AMTI\">Applied Molecular Transport Inc.</a> </strong>(NASDAQ:AMTI)</li>\n<li><strong>argenx SE – ADR </strong>(NASDAQ:ARGX)</li>\n<li><strong><a href=\"https://laohu8.com/S/AUPH\">Aurinia Pharmaceuticals Inc</a> </strong>(NASDAQ:AUPH) (announced FDA approval for its oral lupus nephritis drug)</li>\n<li><strong>Axonics Modulation Technologies Inc </strong>(NASDAQ:AXNX)</li>\n<li><strong>Beigene Ltd </strong>(NASDAQ:BGNE)</li>\n<li><strong>BioNano Genomics Inc </strong>(NASDAQ:BNGO) (reacted to positive sell-side commentary)</li>\n<li><strong><a href=\"https://laohu8.com/S/SAVA\">Cassava Sciences Inc</a> </strong>(NASDAQ:SAVA)</li>\n<li><strong><a href=\"https://laohu8.com/S/CCXI\">ChemoCentryx</a> Inc </strong>(NASDAQ:CCXI)</li>\n<li><strong>Clearpoint Neuro Inc </strong>(NASDAQ:CLPT)</li>\n<li><strong>DarioHealth Corp </strong>(NASDAQ:DRIO)</li>\n<li><strong>DermTech Inc </strong>(NASDAQ:DMTK)</li>\n<li><strong><a href=\"https://laohu8.com/S/EDAP\">Edap Tms SA</a></strong>(NASDAQ:EDAP)</li>\n<li><strong>Eli Lilly And Co </strong>(NYSE:LLY) (reacted to positive Phase 3 data for its COVID-19 antibody treatment bamlanivimab)</li>\n<li><strong><a href=\"https://laohu8.com/S/EKSO\">Ekso Bionics Holdings Inc</a> </strong>(NASDAQ:EKSO)</li>\n<li><strong><a href=\"https://laohu8.com/S/NDRA\">ENDRA Life Sciences Inc</a> </strong>(NASDAQ:NDRA)</li>\n<li><strong>Evogene Ltd </strong>(NASDAQ:EVGN)</li>\n<li><strong>EXACT Sciences Corporation </strong>(NASDAQ:EXAS)</li>\n<li><strong>GW Pharmaceuticals <a href=\"https://laohu8.com/S/PLC\">PLC</a>- ADR </strong>(NASDAQ:GWPH)</li>\n<li><strong>Halozyme Therapeutics, Inc. </strong>(NASDAQ:HALO)</li>\n<li><strong>Harvard Bioscience, Inc. </strong>(NASDAQ:HBIO)</li>\n<li><strong><a href=\"https://laohu8.com/S/ILMN\">Illumina</a>, Inc. </strong>(NASDAQ:ILMN)</li>\n<li><strong>Inari Medical Inc </strong>(NASDAQ:NARI)</li>\n<li><strong><a href=\"https://laohu8.com/S/INSM\">Insmed</a> Incorporated </strong>(NASDAQ:INSM)</li>\n<li><strong>Ionis Pharmaceuticals Inc </strong>(NASDAQ:IONS)</li>\n<li><strong>Jazz Pharmaceuticals PLC </strong>(NASDAQ: JAZZ</li>\n<li><strong>Jounce Therapeutics Inc</strong>(NASDAQ:JNCE)</li>\n<li><strong>Kintara Therapeutics Inc </strong>(NASDAQ:KTRA)</li>\n<li><strong>Krystal Biotech Inc</strong>(NASDAQ:KRYS)</li>\n<li><strong>LeMaitre Vascular Inc </strong>(NASDAQ:LMAT)</li>\n<li><strong><a href=\"https://laohu8.com/S/LGND\">Ligand Pharmaceuticals Inc.</a> </strong>(NASDAQ:LGND)</li>\n<li><strong><a href=\"https://laohu8.com/S/MMSI\">Merit Medical Systems</a>, Inc. </strong>(NASDAQ:MMSI)</li>\n<li><strong>Mustang Bio Inc </strong>(NASDAQ:MBIO)</li>\n<li><strong><a href=\"https://laohu8.com/S/OMCL\">Omnicell</a>, Inc. </strong>(NASDAQ:OMCL)</li>\n<li><strong>Oramed Pharmaceuticals, Inc. </strong>(NASDAQ:ORMP)</li>\n<li><strong><a href=\"https://laohu8.com/S/PEN\">Penumbra Inc</a> </strong>(NYSE:PEN)</li>\n<li><strong>Profound Medical Corp</strong>(NASDAQ:PROF)</li>\n<li><strong>Pulse Biosciences Inc </strong>(NASDAQ:PLSE) (announced CE mark approval for the CellFX System for the treatment of general dermatologic conditions)</li>\n<li><strong>Renalytix AI PLC </strong>(NASDAQ:RNLX)</li>\n<li><strong>Rhythm Pharmaceuticals Inc </strong>(NASDAQ:RYTM)</li>\n<li><strong>Seelos Therapeutics Inc </strong>(NASDAQ:SEEL)</li>\n<li><strong>SI-Bone Inc </strong>(NASDAQ:SIBN)</li>\n<li><strong>Silence Therapeutics ADR Representing 3 Ord Shs </strong>(NASDAQ:SLN)</li>\n<li><strong>SpringWorks Therapeutics Inc </strong>(NASDAQ:SWTX)</li>\n<li><strong><a href=\"https://laohu8.com/S/SUPN\">Supernus Pharmaceuticals</a> Inc </strong>(NASDAQ:SUPN)</li>\n<li><strong><a href=\"https://laohu8.com/S/TMDI\">Titan Medical Inc.</a> </strong>(NASDAQ:TMDI)</li>\n<li><strong>Vericel Corp </strong>(NASDAQ:VCEL)</li>\n<li><strong>Vistagen Therapeutics Inc </strong>(NASDAQ:VTGN)</li>\n</ul>\n<h3>Down In The Dumps</h3>\n<p>None of the biotech/medical device/diagnostic stocks hit 52-week highs in the session.</p>\n<h3>Stocks In Focus</h3>\n<h3>Novartis Q4 Results Trail Expectations</h3>\n<p><strong>Novartis AG </strong>(NYSE:NVS) reported a 3% year-over-year increase in fourth-quarter sales to $12.77 billion. The core EPS increased from $1.32 to $1.34. Analysts, on average, estimated EPS of $1.36 on revenue of $12.87 billion.</p>\n<p>For 2021, the company expects constant currency sales growth in the low-to-mid single digit range and core operating income to rise in the mid-single digit range.</p>\n<p>The stock was down 3.77% to $94.76 premarket Tuesday.</p>\n<h3>Amarin Includes HealthNet In Patent Infringement Lawsuit</h3>\n<p><strong>Amarin Corporation plc </strong>(NASDAQ:AMRN) said it has expanded the scope of its  Vascepa patent infringement lawsuit  against Hikma Pharma to include Health Net, a health care insurance provider in the U.S.</p>\n<p>Amarin alleged that Health Net has actively induced pharmacies to dispense, and patients to use, Hikma generic icosapent ethyl capsules in infringement of three U.S. patents related to Vascepa.</p>\n<p>A vast majority of Vascepa prescriptions are for use in cardiovascular risk reduction, and Hikma does not have an FDA-approved indication for that use, and inducement for such use would infringe the subject patents, Amarin said.</p>\n<p>Amarin shares were rising 2.12% to $7.72 premarket Tuesday. </p>\n<h3>Spectrum Pharma Rises On Fund Stake Disclosure</h3>\n<p><strong><a href=\"https://laohu8.com/S/SPPI\">Spectrum Pharmaceuticals</a>, Inc. </strong>(NASDAQ:SPPI) shares rallied after <strong>BlackRock, Inc. </strong>(NYSE:BLK) revealed in a filing it beneficially owns an aggregate of 27.82 million shares in the company, giving it a 19.1% stake.</p>\n<p>The stock was up 2.55% to $4.02 premarket. </p>\n<p><em>Related Link: The Week Ahead In Biotech (Jan 24-30): J&amp;J, Lilly to Kickstart Big Pharma Earnings, Amgen FDA Decision and More </em></p>\n<h3>Lilly's Antibody Combo Treatment Aces Late-Stage Study In High-Risk COVID-19 Patients</h3>\n<p>Lilly said its bamlanivimab, 2,800 mg, and etesevimab, 2,800 mg, together significantly reduced COVID-19-related hospitalizations and deaths in high-risk patients recently diagnosed with COVID-19, meeting the primary endpoint of the Phase 3 BLAZE-1 trial.</p>\n<p>\"Notably, the 70 percent decrease in risk of hospitalizations or death seen in this Phase 3 trial of bamlanivimab and etesevimab together is consistent with the reduction in risk of hospitalization or ER visits seen with bamlanivimab alone in the Phase 2 trial,\" Lilly said.</p>\n<p>In premarket trading Tuesday, the shares were advancing 1.18% to $214.85. </p>\n<h3>Morphosys Set For $1.5M Milestone Payment From I-Mab As Phase 1 Study Of Monoclonal Antibody In Solid Tumors Commences</h3>\n<p><strong>I-Mab ADR </strong>(NASDAQ:IMAB) and <strong>Morphosys Ag </strong>(NASDAQ:MOR) announced the commencement of a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of MOR210/TJ210 monotherapy in patients with relapsed or refractory advanced solid tumors in the U.S., with the first patient being dosed.</p>\n<p>MOR210/TJ210 is a monoclonal antibody developed by MorphoSys that is directed against complement factor C5a receptor 1.</p>\n<p>MorphoSys will receive a $1.5-million payment from I-Mab for achieving this milestone under the license agreement between the two companies. The licensing deal between the companies announced in November 2018 provides I-Mab exclusive rights to develop and commercialize MOR210/TJ210 in Greater China and South Korea, while MorphoSys retains rights in other parts of the world.</p>\n<p>In premarket trading Tuesday, I-Mab shares were moving up 2.78% to $54.44.</p>\n<h3>Axonics Q4, FY20 Revenue Guidance Below Consensus Estimates</h3>\n<p>Axonics Modulation preannounced fourth-quarter revenue in the range of $34.7 million to $34.9 million, sharply higher than the $9.9 million in the year-ago quarter. For the full-year, the company expects revenue of about $111.5 million compared to the year-ago revenue of $13.8 million.</p>\n<p>The guidance range trailed the consensus estimates that call for revenue of $35.48 million for the quarter and $112.31 million for the year.</p>\n<h3>Merck's Keytruda Gets Label Expansion In Europe</h3>\n<p><strong>Merck &amp; Co., Inc. </strong>(NYSE:MRK) said the European Commission has approved its Keytruda as a monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.</p>\n<p>The stock was down 0.18% to $81 in premarket trading Tuesday.</p>\n<h3>Offerings</h3>\n<p>German  coronavirus vaccine developer  <strong>CureVac BV </strong>(NASDAQ:CVAC) announced an underwritten public offering of 5 million common shares.</p>\n<p>The stock was down 2.6% to $101.78 premarket Tuesday. </p>\n<p>Seelos said it has commenced a proposed underwritten public offering of shares of common stock. All of the shares of common stock in the offering will be sold by the company.</p>\n<p>The stock was tumbling 9.02% to $2.42 premarket Tuesday.</p>\n<p><strong><a href=\"https://laohu8.com/S/LPCN\">Lipocine Inc</a> </strong>(NASDAQ:LPCN) said it intends to offer shares of its common stock in an underwritten public offering. All of the shares in the proposed offering are to be sold by Lipocine.</p>\n<p>In premarket trading Tuesday, the stock was retreating 11.36% to $1.95. </p>\n<h3>On The Radar</h3>\n<p><strong>Clinical Readouts</strong></p>\n<p>Rhythm Pharma is hosting a virtual event from 8-10 a.m. Tuesday to provide an update on its ongoing exploratory Phase 2 Basket Study and genetic sequencing efforts.</p>\n<p>The company will present data for setmelanotide in individuals living with heterozygous obesity due to genetic variants in <a href=\"https://laohu8.com/S/AONE\">one</a> of two alleles of the POMC, PCSK1 or LEPR gene, as well as SRC1 and SH2B1 deficiency obesities.</p>\n<p>It will also provide an update on data from its sequencing efforts, which now comprise samples from approximately 37,500 individuals with severe obesity.</p>\n<h3>Earnings</h3>\n<p><strong>Johnson &amp; Johnson </strong>(NYSE:JNJ) (Q4 revenue of $22.48 billion vs. $21.67-billion estimate, adjusted EPS $1.86 vs. $1.82 consensus, FY21 adjusted EPS guidance above consensus)</p>\n<p><strong>Varian Medical Systems, Inc. </strong>(NYSE:VAR) (after the close)</p>\n<p><em>Related Link: Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates </em></p>\n</body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"OMCL":"Omnicell","MRK":"默沙东","LMAT":"勒梅特微管医疗","AXNX":"Axonics Inc.","MMSI":"Merit Medical Systems","RNLX":"Renalytix AI plc","JNJ":"强生","CCXI":"ChemoCentryx","SEEL":"Seelos Therapeutics, Inc.","INSM":"Insmed","KRYS":"Krystal Biotech Inc.","IMAB":"天境生物","SUPN":"Supernus Pharmaceuticals","RYTM":"Rhythm Pharmaceuticals Inc.","MBIO":"Mustang Bio, Inc","EDAP":"Edap Tms SA","EXAS":"精密科学","ALNY":"阿尔尼拉姆制药公司","LGND":"Ligand Pharmaceuticals Inc.","ALXN":"亚力兄制药","GWPH":"GW Pharmaceuticals plc","CLPT":"ClearPoint Neuro, Inc.","NARI":"Inari Medical, Inc.","AMRN":"阿玛琳","VTGN":"VistaGen Therapeutics, Inc.","SAVA":"Cassava Sciences Inc","IONS":"Ionis Pharmaceuticals, Inc","SPPI":"Spectrum Pharmaceuticals","HALO":"奥洛兹美医疗","SIBN":"SI-BONE, Inc.","MOR":"Morphosys AG","CVAC":"CureVac B.V.","ILMN":"Illumina","VCEL":"Vericel Corporation","DRIO":"DarioHealth","LPCN":"Lipocine Inc","ORMP":"Oramed Pharmaceuticals Inc.","LLY":"礼来","NDRA":"ENDRA Life Sciences Inc","SWTX":"SpringWorks Therapeutics, Inc.","SLN":"Silence Therapeutics Plc","ARGX":"Argenx SE","PROF":"Profound Medical Corp.","PEN":"Penumbra Inc","AMTI":"Applied Molecular Transport Inc."},"source_url":"https://www.benzinga.com/node/19317089","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2106729114","content_text":"Here's a roundup of top developments in the biotech space over the last 24 hours:\nScaling The Peaks\n(Biotech Stocks Hitting 52-week Highs Jan. 25)\n\nAbbott Laboratories (NYSE:ABT)\nAlexion Pharmaceuticals, Inc. (NASDAQ:ALXN)\nAlnylam Pharmaceuticals, Inc. (NASDAQ:ALNY)\nAntares Pharma Inc (NASDAQ:ATRS)\nApplied Molecular Transport Inc. (NASDAQ:AMTI)\nargenx SE – ADR (NASDAQ:ARGX)\nAurinia Pharmaceuticals Inc (NASDAQ:AUPH) (announced FDA approval for its oral lupus nephritis drug)\nAxonics Modulation Technologies Inc (NASDAQ:AXNX)\nBeigene Ltd (NASDAQ:BGNE)\nBioNano Genomics Inc (NASDAQ:BNGO) (reacted to positive sell-side commentary)\nCassava Sciences Inc (NASDAQ:SAVA)\nChemoCentryx Inc (NASDAQ:CCXI)\nClearpoint Neuro Inc (NASDAQ:CLPT)\nDarioHealth Corp (NASDAQ:DRIO)\nDermTech Inc (NASDAQ:DMTK)\nEdap Tms SA(NASDAQ:EDAP)\nEli Lilly And Co (NYSE:LLY) (reacted to positive Phase 3 data for its COVID-19 antibody treatment bamlanivimab)\nEkso Bionics Holdings Inc (NASDAQ:EKSO)\nENDRA Life Sciences Inc (NASDAQ:NDRA)\nEvogene Ltd (NASDAQ:EVGN)\nEXACT Sciences Corporation (NASDAQ:EXAS)\nGW Pharmaceuticals PLC- ADR (NASDAQ:GWPH)\nHalozyme Therapeutics, Inc. (NASDAQ:HALO)\nHarvard Bioscience, Inc. (NASDAQ:HBIO)\nIllumina, Inc. (NASDAQ:ILMN)\nInari Medical Inc (NASDAQ:NARI)\nInsmed Incorporated (NASDAQ:INSM)\nIonis Pharmaceuticals Inc (NASDAQ:IONS)\nJazz Pharmaceuticals PLC (NASDAQ: JAZZ\nJounce Therapeutics Inc(NASDAQ:JNCE)\nKintara Therapeutics Inc (NASDAQ:KTRA)\nKrystal Biotech Inc(NASDAQ:KRYS)\nLeMaitre Vascular Inc (NASDAQ:LMAT)\nLigand Pharmaceuticals Inc. (NASDAQ:LGND)\nMerit Medical Systems, Inc. (NASDAQ:MMSI)\nMustang Bio Inc (NASDAQ:MBIO)\nOmnicell, Inc. (NASDAQ:OMCL)\nOramed Pharmaceuticals, Inc. (NASDAQ:ORMP)\nPenumbra Inc (NYSE:PEN)\nProfound Medical Corp(NASDAQ:PROF)\nPulse Biosciences Inc (NASDAQ:PLSE) (announced CE mark approval for the CellFX System for the treatment of general dermatologic conditions)\nRenalytix AI PLC (NASDAQ:RNLX)\nRhythm Pharmaceuticals Inc (NASDAQ:RYTM)\nSeelos Therapeutics Inc (NASDAQ:SEEL)\nSI-Bone Inc (NASDAQ:SIBN)\nSilence Therapeutics ADR Representing 3 Ord Shs (NASDAQ:SLN)\nSpringWorks Therapeutics Inc (NASDAQ:SWTX)\nSupernus Pharmaceuticals Inc (NASDAQ:SUPN)\nTitan Medical Inc. (NASDAQ:TMDI)\nVericel Corp (NASDAQ:VCEL)\nVistagen Therapeutics Inc (NASDAQ:VTGN)\n\nDown In The Dumps\nNone of the biotech/medical device/diagnostic stocks hit 52-week highs in the session.\nStocks In Focus\nNovartis Q4 Results Trail Expectations\nNovartis AG (NYSE:NVS) reported a 3% year-over-year increase in fourth-quarter sales to $12.77 billion. The core EPS increased from $1.32 to $1.34. Analysts, on average, estimated EPS of $1.36 on revenue of $12.87 billion.\nFor 2021, the company expects constant currency sales growth in the low-to-mid single digit range and core operating income to rise in the mid-single digit range.\nThe stock was down 3.77% to $94.76 premarket Tuesday.\nAmarin Includes HealthNet In Patent Infringement Lawsuit\nAmarin Corporation plc (NASDAQ:AMRN) said it has expanded the scope of its  Vascepa patent infringement lawsuit  against Hikma Pharma to include Health Net, a health care insurance provider in the U.S.\nAmarin alleged that Health Net has actively induced pharmacies to dispense, and patients to use, Hikma generic icosapent ethyl capsules in infringement of three U.S. patents related to Vascepa.\nA vast majority of Vascepa prescriptions are for use in cardiovascular risk reduction, and Hikma does not have an FDA-approved indication for that use, and inducement for such use would infringe the subject patents, Amarin said.\nAmarin shares were rising 2.12% to $7.72 premarket Tuesday. \nSpectrum Pharma Rises On Fund Stake Disclosure\nSpectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) shares rallied after BlackRock, Inc. (NYSE:BLK) revealed in a filing it beneficially owns an aggregate of 27.82 million shares in the company, giving it a 19.1% stake.\nThe stock was up 2.55% to $4.02 premarket. \nRelated Link: The Week Ahead In Biotech (Jan 24-30): J&J, Lilly to Kickstart Big Pharma Earnings, Amgen FDA Decision and More \nLilly's Antibody Combo Treatment Aces Late-Stage Study In High-Risk COVID-19 Patients\nLilly said its bamlanivimab, 2,800 mg, and etesevimab, 2,800 mg, together significantly reduced COVID-19-related hospitalizations and deaths in high-risk patients recently diagnosed with COVID-19, meeting the primary endpoint of the Phase 3 BLAZE-1 trial.\n\"Notably, the 70 percent decrease in risk of hospitalizations or death seen in this Phase 3 trial of bamlanivimab and etesevimab together is consistent with the reduction in risk of hospitalization or ER visits seen with bamlanivimab alone in the Phase 2 trial,\" Lilly said.\nIn premarket trading Tuesday, the shares were advancing 1.18% to $214.85. \nMorphosys Set For $1.5M Milestone Payment From I-Mab As Phase 1 Study Of Monoclonal Antibody In Solid Tumors Commences\nI-Mab ADR (NASDAQ:IMAB) and Morphosys Ag (NASDAQ:MOR) announced the commencement of a Phase 1 study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of MOR210/TJ210 monotherapy in patients with relapsed or refractory advanced solid tumors in the U.S., with the first patient being dosed.\nMOR210/TJ210 is a monoclonal antibody developed by MorphoSys that is directed against complement factor C5a receptor 1.\nMorphoSys will receive a $1.5-million payment from I-Mab for achieving this milestone under the license agreement between the two companies. The licensing deal between the companies announced in November 2018 provides I-Mab exclusive rights to develop and commercialize MOR210/TJ210 in Greater China and South Korea, while MorphoSys retains rights in other parts of the world.\nIn premarket trading Tuesday, I-Mab shares were moving up 2.78% to $54.44.\nAxonics Q4, FY20 Revenue Guidance Below Consensus Estimates\nAxonics Modulation preannounced fourth-quarter revenue in the range of $34.7 million to $34.9 million, sharply higher than the $9.9 million in the year-ago quarter. For the full-year, the company expects revenue of about $111.5 million compared to the year-ago revenue of $13.8 million.\nThe guidance range trailed the consensus estimates that call for revenue of $35.48 million for the quarter and $112.31 million for the year.\nMerck's Keytruda Gets Label Expansion In Europe\nMerck & Co., Inc. (NYSE:MRK) said the European Commission has approved its Keytruda as a monotherapy for the first-line treatment of adult patients with metastatic microsatellite instability-high or mismatch repair deficient colorectal cancer.\nThe stock was down 0.18% to $81 in premarket trading Tuesday.\nOfferings\nGerman  coronavirus vaccine developer  CureVac BV (NASDAQ:CVAC) announced an underwritten public offering of 5 million common shares.\nThe stock was down 2.6% to $101.78 premarket Tuesday. \nSeelos said it has commenced a proposed underwritten public offering of shares of common stock. All of the shares of common stock in the offering will be sold by the company.\nThe stock was tumbling 9.02% to $2.42 premarket Tuesday.\nLipocine Inc (NASDAQ:LPCN) said it intends to offer shares of its common stock in an underwritten public offering. All of the shares in the proposed offering are to be sold by Lipocine.\nIn premarket trading Tuesday, the stock was retreating 11.36% to $1.95. \nOn The Radar\nClinical Readouts\nRhythm Pharma is hosting a virtual event from 8-10 a.m. Tuesday to provide an update on its ongoing exploratory Phase 2 Basket Study and genetic sequencing efforts.\nThe company will present data for setmelanotide in individuals living with heterozygous obesity due to genetic variants in one of two alleles of the POMC, PCSK1 or LEPR gene, as well as SRC1 and SH2B1 deficiency obesities.\nIt will also provide an update on data from its sequencing efforts, which now comprise samples from approximately 37,500 individuals with severe obesity.\nEarnings\nJohnson & Johnson (NYSE:JNJ) (Q4 revenue of $22.48 billion vs. $21.67-billion estimate, adjusted EPS $1.86 vs. $1.82 consensus, FY21 adjusted EPS guidance above consensus)\nVarian Medical Systems, Inc. (NYSE:VAR) (after the close)\nRelated Link: Attention Biotech Investors: Mark Your Calendar For January PDUFA Dates","news_type":1},"isVote":1,"tweetType":1,"viewCount":148,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":311211644,"gmtCreate":1611798567188,"gmtModify":1704863654770,"author":{"id":"3572496339521414","authorId":"3572496339521414","name":"jazlynnsee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572496339521414","authorIdStr":"3572496339521414"},"themes":[],"htmlText":"moon","listText":"moon","text":"moon","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":1,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/311211644","repostId":"2106281886","repostType":4,"repost":{"id":"2106281886","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1611738637,"share":"https://ttm.financial/m/news/2106281886?lang=&edition=fundamental","pubTime":"2021-01-27 17:10","market":"us","language":"en","title":"GameStop up another 60%, amateur interest shows no sign of abating","url":"https://stock-news.laohu8.com/highlight/detail?id=2106281886","media":"Reuters","summary":"LONDON, Jan 27 (Reuters) - GameStop shares surged another 60% on Wednesday in pre-market trading, bo","content":"<p>LONDON, Jan 27 (Reuters) - GameStop shares surged another 60% on Wednesday in pre-market trading, boosted by increased interest among amateur investors who have lifted the share price by 700% over the past two weeks.</p><p>But some hedge funds have refused to budge from their bearish bets, with FIS' Analytics data showing investors had piled on $2.2 billion in bearish bets on the U.S. video game retailer -- a whopping 20% of its market capitalisation,</p><p>In the meantime, Reddit's Wallstreetbets stock trading discussion group were backing the company, buying shares and  call options on the stock.</p><p>A similar euphoria has boosted BlackBerry and Nokia</p><p>Meanwhile in Europe, shares of Evotec and Varta</p><p>jumped on a chatter that Melvin Capital Management was being forced to unwind its short positions to cover losses on its other bearish bets, including GameStop.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>GameStop up another 60%, amateur interest shows no sign of abating</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGameStop up another 60%, amateur interest shows no sign of abating\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-01-27 17:10</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>LONDON, Jan 27 (Reuters) - GameStop shares surged another 60% on Wednesday in pre-market trading, boosted by increased interest among amateur investors who have lifted the share price by 700% over the past two weeks.</p><p>But some hedge funds have refused to budge from their bearish bets, with FIS' Analytics data showing investors had piled on $2.2 billion in bearish bets on the U.S. video game retailer -- a whopping 20% of its market capitalisation,</p><p>In the meantime, Reddit's Wallstreetbets stock trading discussion group were backing the company, buying shares and  call options on the stock.</p><p>A similar euphoria has boosted BlackBerry and Nokia</p><p>Meanwhile in Europe, shares of Evotec and Varta</p><p>jumped on a chatter that Melvin Capital Management was being forced to unwind its short positions to cover losses on its other bearish bets, including GameStop.</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GME":"游戏驿站","FIS":"繁德信息技术"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2106281886","content_text":"LONDON, Jan 27 (Reuters) - GameStop shares surged another 60% on Wednesday in pre-market trading, boosted by increased interest among amateur investors who have lifted the share price by 700% over the past two weeks.But some hedge funds have refused to budge from their bearish bets, with FIS' Analytics data showing investors had piled on $2.2 billion in bearish bets on the U.S. video game retailer -- a whopping 20% of its market capitalisation,In the meantime, Reddit's Wallstreetbets stock trading discussion group were backing the company, buying shares and  call options on the stock.A similar euphoria has boosted BlackBerry and NokiaMeanwhile in Europe, shares of Evotec and Vartajumped on a chatter that Melvin Capital Management was being forced to unwind its short positions to cover losses on its other bearish bets, including GameStop.","news_type":1},"isVote":1,"tweetType":1,"viewCount":154,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":311210246,"gmtCreate":1611798295885,"gmtModify":1704863650724,"author":{"id":"3572496339521414","authorId":"3572496339521414","name":"jazlynnsee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572496339521414","authorIdStr":"3572496339521414"},"themes":[],"htmlText":"okay","listText":"okay","text":"okay","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":2,"commentSize":0,"repostSize":0,"link":"https://ttm.financial/post/311210246","repostId":"1164631082","repostType":4,"repost":{"id":"1164631082","pubTimestamp":1611738537,"share":"https://ttm.financial/m/news/1164631082?lang=&edition=fundamental","pubTime":"2021-01-27 17:08","market":"us","language":"en","title":"Airbnb was ensnared in the Capitol Riot fallout. It somehow still came out on top","url":"https://stock-news.laohu8.com/highlight/detail?id=1164631082","media":"CNN","summary":"Washington, DCBrian Chesky had some air mattresses, but not much more, in 2008 when the presidential","content":"<p>Washington, DCBrian Chesky had some air mattresses, but not much more, in 2008 when the presidential election triggered an idea for his then-fledgling startup, Airbnb.</p><p>To draw attention to their site, Chesky and his co-founders started selling politically themed cereals. There were Obama-os, \"the breakfast of change,\" and Captain McCains, \"a maverick in every bite,\" as Chesky has recalled in interviews. Money had been so tight that year, Chesky said, that he lost 20 pounds as he ate less.</p><p>Luckily, the cereal gimmick was a hit, selling out in days, Chesky said in a 2013 interview with the tech publication Pando. Airbnb sold about $30,000 of cereal, and got mostly out of debt, he said. Politics could be part of the marketing strategy, especially for a company just scraping by.</p><p>Just over 13 years later, Chesky doesn't have to worry about his next meal. He's worth billions of dollars after Airbnb's December 2020 initial public offering. The company's stock doubled on its first day.<img src=\"https://static.tigerbbs.com/0e7d4d647e7690267a9657798b0a1a43\" tg-width=\"1100\" tg-height=\"619\" referrerpolicy=\"no-referrer\">But the most recent presidential election and inauguration have proven radically different than the first for which Airbnb was around.</p><p>In a world in which American corporations can no longer maintain a sense of detached indifference, Chesky and Airbnb must increasingly wrangle with politics and power beyond what a company like Airbnb would usually have to deal with, as Washington, DC's violent insurrection illustrated. Few in the hospitality industry could have imagined having to consider issues like an insurrection when Chesky first launched Airbnb.</p><p>But somehow, Chesky and Airbnb might come out on top all over again.</p><p><b>Airbnb makes a call</b></p><p>Earlier this month, Airbnb hosts were alarmed to find their homes used as staging grounds for violence. Calls came for Airbnb and competitors to restrict rentals.</p><p>\"Residents throughout the District endured severe trauma with evacuations of residences and businesses,\" wrote 70 DC Advisory Neighborhood Commissions, neighborhood governing bodies of elected officials, in a letter calling for hotels, Airbnb and VRBO to not rent during inauguration week. \"There are strong indications these individuals plan to return to the District during Inauguration week to wreak havoc on our city.\"</p><p>Organizers calling for a DC shutdown said that their volunteers messaged 3,400 DC Airbnb hosts and encouraged them not to rent their properties.</p><p>Chesky and Airbnb faced questions of their responsibility to the American democracy. Any move in either direction could have had a significant financial impact on Airbnb, as presidential inaugurations historically attract thousands of visitors who are willing to pay top dollar to stay in the nation's capital.</p><p>Chesky had to navigate the question of whether his response to the insurrection would be well-received by Wall Street investors. Airbnb's reputation was on the line.</p><p>Get it right, and Chesky would look like a responsible corporate steward. (Both Chesky and Airbnb declined to comment for this story.)</p><p>Days after the Capitol insurrection, Airbnb released a \"Capitol Safety Plan,\" saying it would review DC reservations and ban individuals involved in criminal activity at the Capitol. But that didn't quiet critics. DC residents continued to call on Airbnb to halt reservations. Government officials like DC Mayor Muriel Bowser, Virginia Gov. Ralph Northam and Maryland Gov. Larry Hogan called for people to not attend the inauguration in person.</p><p>Chesky announced a revised plan Jan. 13, canceling all short-term reservations in the greater Washington, DC area, not only refunding guests' payments, but reimbursing lost reservation income to hosts, too. Long-term reservations that extended outside Jan. 15-21 were unaffected.</p><p>The move was a much different response than competing hotels and online travel sites like VRBO, which have generally remained open.</p><p>Peter Kern, CEO of VRBO's parent company Expedia told CNN Business Jan. 18 that there were \"a lot of completely legitimate and appropriate uses of the properties.\" A day later, though, Expedia announced that new reservations would be blocked in Washington, DC, following updated guidance from government officials.</p><p>In a blog post in which it announced its decision Airbnb warned of \"armed militias and known hate groups that are attempting to travel and disrupt the Inauguration\" in its blog post.</p><p>Airbnb seems to have navigated the situation without any major issues. But doing so wasn't a given.<img src=\"https://static.tigerbbs.com/4f9fb2f68842845e3bc9d345d3d28526\" tg-width=\"1100\" tg-height=\"619\" referrerpolicy=\"no-referrer\">It was unclear before the inauguration how effective Airbnb's reservation review process was, and if it led to meaningful cancellations, or any at all. Airbnb declined to say how many cancellations were made before the inauguration. Its competitor, VRBO, also declined to say if its own reviews had led to cancellations.</p><p>Airbnb's policy did not appear to be comprehensive in addressing potential for violence in state capitals. While Airbnb had publicly said it reviewed reservations in select state capitals, such as Lansing, Sacramento, Olympia and Carson City, it declined to say before the inauguration if it had done so in every state capital.</p><p><b>Airbnb looks ahead</b></p><p>Airbnb has set a precedent on how it will deal with risk of violence at major events like presidential inaugurations, whether it's from the far-right as was the case this month, or other groups. While similar events will hopefully be rare, some in the travel industry are taking notice and seeking more collaboration to improve safety.</p><p>Tori Emerson Barnes, executive vice president, public affairs and policy at U.S. Travel Association, which represents travel industry companies like Airbnb and Expedia Group, believes that there could be more coordination and information sharing in the future to benefit the industry. Hotels and rental car companies could receive the same access to security threats as airlines do.</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Airbnb was ensnared in the Capitol Riot fallout. It somehow still came out on top</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAirbnb was ensnared in the Capitol Riot fallout. It somehow still came out on top\n</h2>\n\n<h4 class=\"meta\">\n\n\n2021-01-27 17:08 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://edition.cnn.com/2021/01/26/business/airbnb-risk-takers/index.html><strong>CNN</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Washington, DCBrian Chesky had some air mattresses, but not much more, in 2008 when the presidential election triggered an idea for his then-fledgling startup, Airbnb.To draw attention to their site, ...</p>\n\n<a href=\"https://edition.cnn.com/2021/01/26/business/airbnb-risk-takers/index.html\">Web Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{},"source_url":"https://edition.cnn.com/2021/01/26/business/airbnb-risk-takers/index.html","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1164631082","content_text":"Washington, DCBrian Chesky had some air mattresses, but not much more, in 2008 when the presidential election triggered an idea for his then-fledgling startup, Airbnb.To draw attention to their site, Chesky and his co-founders started selling politically themed cereals. There were Obama-os, \"the breakfast of change,\" and Captain McCains, \"a maverick in every bite,\" as Chesky has recalled in interviews. Money had been so tight that year, Chesky said, that he lost 20 pounds as he ate less.Luckily, the cereal gimmick was a hit, selling out in days, Chesky said in a 2013 interview with the tech publication Pando. Airbnb sold about $30,000 of cereal, and got mostly out of debt, he said. Politics could be part of the marketing strategy, especially for a company just scraping by.Just over 13 years later, Chesky doesn't have to worry about his next meal. He's worth billions of dollars after Airbnb's December 2020 initial public offering. The company's stock doubled on its first day.But the most recent presidential election and inauguration have proven radically different than the first for which Airbnb was around.In a world in which American corporations can no longer maintain a sense of detached indifference, Chesky and Airbnb must increasingly wrangle with politics and power beyond what a company like Airbnb would usually have to deal with, as Washington, DC's violent insurrection illustrated. Few in the hospitality industry could have imagined having to consider issues like an insurrection when Chesky first launched Airbnb.But somehow, Chesky and Airbnb might come out on top all over again.Airbnb makes a callEarlier this month, Airbnb hosts were alarmed to find their homes used as staging grounds for violence. Calls came for Airbnb and competitors to restrict rentals.\"Residents throughout the District endured severe trauma with evacuations of residences and businesses,\" wrote 70 DC Advisory Neighborhood Commissions, neighborhood governing bodies of elected officials, in a letter calling for hotels, Airbnb and VRBO to not rent during inauguration week. \"There are strong indications these individuals plan to return to the District during Inauguration week to wreak havoc on our city.\"Organizers calling for a DC shutdown said that their volunteers messaged 3,400 DC Airbnb hosts and encouraged them not to rent their properties.Chesky and Airbnb faced questions of their responsibility to the American democracy. Any move in either direction could have had a significant financial impact on Airbnb, as presidential inaugurations historically attract thousands of visitors who are willing to pay top dollar to stay in the nation's capital.Chesky had to navigate the question of whether his response to the insurrection would be well-received by Wall Street investors. Airbnb's reputation was on the line.Get it right, and Chesky would look like a responsible corporate steward. (Both Chesky and Airbnb declined to comment for this story.)Days after the Capitol insurrection, Airbnb released a \"Capitol Safety Plan,\" saying it would review DC reservations and ban individuals involved in criminal activity at the Capitol. But that didn't quiet critics. DC residents continued to call on Airbnb to halt reservations. Government officials like DC Mayor Muriel Bowser, Virginia Gov. Ralph Northam and Maryland Gov. Larry Hogan called for people to not attend the inauguration in person.Chesky announced a revised plan Jan. 13, canceling all short-term reservations in the greater Washington, DC area, not only refunding guests' payments, but reimbursing lost reservation income to hosts, too. Long-term reservations that extended outside Jan. 15-21 were unaffected.The move was a much different response than competing hotels and online travel sites like VRBO, which have generally remained open.Peter Kern, CEO of VRBO's parent company Expedia told CNN Business Jan. 18 that there were \"a lot of completely legitimate and appropriate uses of the properties.\" A day later, though, Expedia announced that new reservations would be blocked in Washington, DC, following updated guidance from government officials.In a blog post in which it announced its decision Airbnb warned of \"armed militias and known hate groups that are attempting to travel and disrupt the Inauguration\" in its blog post.Airbnb seems to have navigated the situation without any major issues. But doing so wasn't a given.It was unclear before the inauguration how effective Airbnb's reservation review process was, and if it led to meaningful cancellations, or any at all. Airbnb declined to say how many cancellations were made before the inauguration. Its competitor, VRBO, also declined to say if its own reviews had led to cancellations.Airbnb's policy did not appear to be comprehensive in addressing potential for violence in state capitals. While Airbnb had publicly said it reviewed reservations in select state capitals, such as Lansing, Sacramento, Olympia and Carson City, it declined to say before the inauguration if it had done so in every state capital.Airbnb looks aheadAirbnb has set a precedent on how it will deal with risk of violence at major events like presidential inaugurations, whether it's from the far-right as was the case this month, or other groups. While similar events will hopefully be rare, some in the travel industry are taking notice and seeking more collaboration to improve safety.Tori Emerson Barnes, executive vice president, public affairs and policy at U.S. Travel Association, which represents travel industry companies like Airbnb and Expedia Group, believes that there could be more coordination and information sharing in the future to benefit the industry. Hotels and rental car companies could receive the same access to security threats as airlines do.","news_type":1},"isVote":1,"tweetType":1,"viewCount":260,"authorTweetTopStatus":1,"verified":2,"comments":[],"imageCount":0,"langContent":"EN","totalScore":0},{"id":311234561,"gmtCreate":1611798110253,"gmtModify":1704863648128,"author":{"id":"3572496339521414","authorId":"3572496339521414","name":"jazlynnsee","avatar":"https://static.laohu8.com/default-avatar.jpg","crmLevel":2,"crmLevelSwitch":0,"followedFlag":false,"idStr":"3572496339521414","authorIdStr":"3572496339521414"},"themes":[],"htmlText":"wow","listText":"wow","text":"wow","images":[],"top":1,"highlighted":1,"essential":1,"paper":1,"likeSize":0,"commentSize":1,"repostSize":0,"link":"https://ttm.financial/post/311234561","repostId":"2106028900","repostType":4,"repost":{"id":"2106028900","weMediaInfo":{"introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"media_name":"Reuters","id":"1036604489","head_image":"https://static.tigerbbs.com/443ce19704621c837795676028cec868"},"pubTimestamp":1611739980,"share":"https://ttm.financial/m/news/2106028900?lang=&edition=fundamental","pubTime":"2021-01-27 17:33","market":"us","language":"en","title":"Goldman Sachs loses legal fight against EU cartel fine","url":"https://stock-news.laohu8.com/highlight/detail?id=2106028900","media":"Reuters","summary":"BRUSSELS, Jan 27 (Reuters) - U.S. investment bank Goldman Sachs on Wednesday lost its fight against ","content":"<p>BRUSSELS, Jan 27 (Reuters) - U.S. investment bank Goldman Sachs&nbsp;on Wednesday lost its fight against an EU cartel fine handed down to its former Italian subsidiary and cable maker Prysmian after Europe's top court said it was liable for the actions of the unit.</p><p>Prysmian was fined 104.6 million euros ($127 million) by EU antitrust regulators in 2014 for taking part in a cartel with 10 other cable makers.</p><p>Its penalty included a joint fine of 37.3 million euros with Goldman Sachs, which had acquired the Italian company via <a href=\"https://laohu8.com/S/AONE\">one</a> of its private equity funds in 2005 but has since sold its holding.</p><p>The European Commission in its 2014 decision said Goldman Sachs, as the parent company, had decisive influence over Prysmian. A lower EU tribunal in 2018 backed its argument.</p><p>The Luxembourg-based Court of Justice of the European Union (CJEU) agreed with the reasoning and rejected Goldman Sachs' appeal.</p><p>\"The General Court did not err in law in finding that, in the present case, the Commission was entitled to rely on a presumption of actual exercise of decisive influence in order to establish the appellant's liability for the infringement at issue in relation to the pre-IPO period,\" CJEU judges said.</p><p>The case is C-595/18 P The Goldman Sachs Group v Commission.</p><p>($1 = 0.8232 euros)</p>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Goldman Sachs loses legal fight against EU cartel fine</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGoldman Sachs loses legal fight against EU cartel fine\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036604489\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/443ce19704621c837795676028cec868);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2021-01-27 17:33</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>BRUSSELS, Jan 27 (Reuters) - U.S. investment bank Goldman Sachs&nbsp;on Wednesday lost its fight against an EU cartel fine handed down to its former Italian subsidiary and cable maker Prysmian after Europe's top court said it was liable for the actions of the unit.</p><p>Prysmian was fined 104.6 million euros ($127 million) by EU antitrust regulators in 2014 for taking part in a cartel with 10 other cable makers.</p><p>Its penalty included a joint fine of 37.3 million euros with Goldman Sachs, which had acquired the Italian company via <a href=\"https://laohu8.com/S/AONE\">one</a> of its private equity funds in 2005 but has since sold its holding.</p><p>The European Commission in its 2014 decision said Goldman Sachs, as the parent company, had decisive influence over Prysmian. A lower EU tribunal in 2018 backed its argument.</p><p>The Luxembourg-based Court of Justice of the European Union (CJEU) agreed with the reasoning and rejected Goldman Sachs' appeal.</p><p>\"The General Court did not err in law in finding that, in the present case, the Commission was entitled to rely on a presumption of actual exercise of decisive influence in order to establish the appellant's liability for the infringement at issue in relation to the pre-IPO period,\" CJEU judges said.</p><p>The case is C-595/18 P The Goldman Sachs Group v Commission.</p><p>($1 = 0.8232 euros)</p>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"GS":"高盛"},"is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"2106028900","content_text":"BRUSSELS, Jan 27 (Reuters) - U.S. investment bank Goldman Sachs on Wednesday lost its fight against an EU cartel fine handed down to its former Italian subsidiary and cable maker Prysmian after Europe's top court said it was liable for the actions of the unit.Prysmian was fined 104.6 million euros ($127 million) by EU antitrust regulators in 2014 for taking part in a cartel with 10 other cable makers.Its penalty included a joint fine of 37.3 million euros with Goldman Sachs, which had acquired the Italian company via one of its private equity funds in 2005 but has since sold its holding.The European Commission in its 2014 decision said Goldman Sachs, as the parent company, had decisive influence over Prysmian. A lower EU tribunal in 2018 backed its argument.The Luxembourg-based Court of Justice of the European Union (CJEU) agreed with the reasoning and rejected Goldman Sachs' appeal.\"The General Court did not err in law in finding that, in the present case, the Commission was entitled to rely on a presumption of actual exercise of decisive influence in order to establish the appellant's liability for the infringement at issue in relation to the pre-IPO period,\" CJEU judges said.The case is C-595/18 P The Goldman Sachs Group v Commission.($1 = 0.8232 euros)","news_type":1},"isVote":1,"tweetType":1,"viewCount":356,"authorTweetTopStatus":1,"verified":2,"comments":[{"author":{"id":"3527667803686145","authorId":"3527667803686145","name":"社区成长助手","avatar":"https://static.tigerbbs.com/2b7c7106b5c0c8b0037faa67439d898f","crmLevel":1,"crmLevelSwitch":0,"idStr":"3527667803686145","authorIdStr":"3527667803686145"},"content":"Finally, when you first post [compare heart] [compare heart] post, you can get more exposure by related stocks or related topics. If you want to create high-quality articles, please checkGuidelines for Tiger Community Creation","text":"Finally, when you first post [compare heart] [compare heart] post, you can get more exposure by related stocks or related topics. If you want to create high-quality articles, please checkGuidelines for Tiger Community Creation","html":"Finally, when you first post [compare heart] [compare heart] post, you can get more exposure by related stocks or related topics. If you want to create high-quality articles, please checkGuidelines for Tiger Community Creation"}],"imageCount":0,"langContent":"EN","totalScore":0}],"defaultTab":"posts","isTTM":true}